← Leaderboards
Pier Paolo Pandolfi
Sloan-Kettering Institute For Cancer Res
$54,825,346
Attributed
$54,825,346
Total exposure
27
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.1M · FY2005–19$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$54,825,346 · 27
By mechanism
R01$23,947,791 · 9
U01$12,312,914 · 3
P50$4,978,386 · 5
R35$4,575,459 · 1
RC2$4,152,659 · 1
R37$1,792,067 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Riccardo Dalla-Favera$29,692,137
- Raju Chaganti$3,696,551
- Derek B. Sant'angelo$12,312,303
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMouse ModelProteinsGenesTumorigenesisBasePathway InteractionsCellsTumorMutantIn VivoGeneticTumor Suppressor ProteinsOncogenesMolecularMediatingResponseTumor SuppressionTumor Suppressor GenesSignal TransductionLaboratory MouseIn VitroPlayGenerations
Grant awards (138)
Targeting Tumor Suppressive Pathways for Cancer Therapy$1,012,680
R35 · FY2019 · CA · contact PI
Targeting PML for Leukemia Therapy$443,273
R01 · FY2019 · CA · contact PI
Targeting Tumor Suppressive Pathways for Cancer Therapy$1,044,000
R35 · FY2018 · CA · contact PI
Targeting PML for Leukemia Therapy$457,619
R01 · FY2018 · CA · contact PI
NPM1 regulation of 2'-O-methylation in hematopoiesis and bone marrow failure disorder$408,289
R01 · FY2018 · DK · contact PI
Project 1: Post-Transcriptional Regulation of the Tumor Suppressor Gene PTEN by Competing Endogenous RNAs (ceRNAs)$186,467
U54 · FY2018 · CA · contact PI
Targeting Tumor Suppressive Pathways for Cancer Therapy$1,044,000
R35 · FY2017 · CA · contact PI
Targeting PML for Leukemia Therapy$465,791
R01 · FY2017 · CA · contact PI
NPM1 regulation of 2'-O-methylation in hematopoiesis and bone marrow failure disorder$408,289
R01 · FY2017 · DK · contact PI
Project 1: Post-Transcriptional Regulation of the Tumor Suppressor Gene PTEN by Competing Endogenous RNAs (ceRNAs)$186,001
U54 · FY2017 · CA · contact PI
Targeting Tumor Suppressive Pathways for Cancer Therapy$1,044,000
R35 · FY2016 · CA · contact PI
Targeting PML for Leukemia Therapy$465,791
R01 · FY2016 · CA · contact PI
Project 1: Post-Transcriptional Regulation of the Tumor Suppressor Gene PTEN by Competing Endogenous RNAs (ceRNAs)$186,999
U54 · FY2016 · CA · contact PI
Targeting Tumor Suppressive Pathways for Cancer Therapy$430,779
R35 · FY2015 · CA · contact PI
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)$361,050
R01 · FY2015 · CA · contact PI
PTEN in ontogenesis and tumor suppression$336,229
R01 · FY2015 · CA · contact PI
Dissecting the Therapeutic Role of Pt3K aod AR Pathway Inhibition In Prostate Cancer$297,413
P50 · FY2015 · CA · contact PI
ANIMAL MODELS CORE$191,743
P50 · FY2015 · CA · contact PI
Targeting PML for leukemia therapy.$436,776
R01 · FY2014 · CA · contact PI
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)$350,219
R01 · FY2014 · CA · contact PI
Role of DOK family proteins in lung tumor suppression$339,713
R01 · FY2014 · CA · contact PI
A metabolic role for PML in tumor suppression$339,713
R01 · FY2014 · CA · contact PI
PTEN in ontogenesis and tumor suppression$326,142
R01 · FY2014 · CA · contact PI
Role of POZ-zinc finger proteins in tumorigenesis.$321,009
R01 · FY2014 · CA · contact PI
Dissecting the Therapeutic Role of Pt3K aod AR Pathway Inhibition In Prostate Cancer$293,189
P50 · FY2014 · CA · contact PI
ANIMAL MODELS CORE$191,563
P50 · FY2014 · CA · contact PI
Targeting Tumor Suppressor Phosphatases For Cancer Therapy$746,599
U01 · FY2013 · CA · contact PI
The Co-Clinical Trial Project$695,315
U01 · FY2013 · CA · contact PI
Targeting PML for leukemia therapy.$425,460
R01 · FY2013 · CA · contact PI
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)$339,387
R01 · FY2013 · CA · contact PI
PTEN in ontogenesis and tumor suppression$336,229
R01 · FY2013 · CA · contact PI
Role of DOK family proteins in lung tumor suppression$329,206
R01 · FY2013 · CA · contact PI
A metabolic role for PML in tumor suppression$329,206
R01 · FY2013 · CA · contact PI
Role of POZ-zinc finger proteins in tumorigenesis.$311,080
R01 · FY2013 · CA · contact PI
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE$297,748
P50 · FY2013 · CA · contact PI
ANIMAL MODELS CORE$192,750
P50 · FY2013 · CA · contact PI
Targeting Tumor Suppressor Phosphatases For Cancer Therapy$801,051
U01 · FY2012 · CA · contact PI
The Co-Clinical Trial Project$741,121
U01 · FY2012 · CA · contact PI
Targeting PML for leukemia therapy.$455,022
R01 · FY2012 · CA · contact PI
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)$361,050
R01 · FY2012 · CA · contact PI
Role of DOK family proteins in lung tumor suppression$350,219
R01 · FY2012 · CA · contact PI
A metabolic role for PML in tumor suppression$350,219
R01 · FY2012 · CA · contact PI
PTEN and ontogenesis and tumor suppression$340,612
R01 · FY2012 · CA · contact PI
Role of POZ-zinc finger proteins in tumorigenesis.$330,937
R01 · FY2012 · CA · contact PI
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE$309,613
P50 · FY2012 · CA · contact PI
Identification and Characterization of Cell Autonomous Determinants that Promote$245,642
U54 · FY2012 · CA · contact PI
ANIMAL MODELS CORE$207,727
P50 · FY2012 · CA · contact PI
Targeting Tumor Suppressor Phosphatases For Cancer Therapy$959,368
U01 · FY2011 · CA · contact PI
Targeting PML for leukemia therapy.$457,498
R01 · FY2011 · CA · contact PI
Role of DOK family proteins in lung tumor suppression$350,219
R01 · FY2011 · CA · contact PI
A metabolic role for PML in tumor suppression$350,219
R01 · FY2011 · CA · contact PI
PTEN and ontogenesis and tumor suppression$340,612
R01 · FY2011 · CA · contact PI
Role of POZ-zinc finger proteins in tumorigenesis.$330,937
R01 · FY2011 · CA · contact PI
The Co-Clinical Trial Project$141,004
U01 · FY2011 · CA · contact PI
The Co-Clinical Project: Informing clinical trials using preclinical mouse models$2,088,292
RC2 · FY2010 · CA · contact PI
Targeting Tumor Suppressor Phosphatases For Cancer Therapy$839,120
U01 · FY2010 · CA · contact PI
The Co-Clinical Trial Project$766,939
U01 · FY2010 · CA · contact PI
Nucleophosmin and ribosomal dysfunction in hematologic diseases$500,000
RC1 · FY2010 · DK · contact PI
Targeting PML for leukemia therapy.$473,271
R01 · FY2010 · CA · contact PI
Role of DOK family proteins in lung tumor suppression$360,618
R01 · FY2010 · CA · contact PI
A metabolic role for PML in tumor suppression$360,359
R01 · FY2010 · CA · contact PI
PTEN and ontogenesis and tumor suppression$351,147
R01 · FY2010 · CA · contact PI
X-RAR alpha proteins: Molecualr Pathogenesis of Acute Promyelocytic Leukemia$348,711
R37 · FY2010 · CA · contact PI
Role of POZ-zinc finger proteins in tumorigenesis.$340,356
R01 · FY2010 · CA · contact PI
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE$334,901
P50 · FY2010 · CA · contact PI
ANIMAL MODELS CORE$299,080
P50 · FY2010 · CA · contact PI
The Co-Clinical Project: Informing clinical trials using preclinical mouse models$2,064,367
RC2 · FY2009 · CA · contact PI
Targeting Tumor Suppressor Phosphatases For Cancer Therapy$825,000
U01 · FY2009 · CA · contact PI
The Co-Clinical Trial Project$750,000
U01 · FY2009 · CA · contact PI
Nucleophosmin and ribosomal dysfunction in hematologic diseases$500,000
RC1 · FY2009 · DK · contact PI
Fusion Proteins in the Molecular Pathogenesis of APL$362,680
R01 · FY2009 · CA · contact PI
PTEN and ontogenesis and tumor suppression$351,147
R01 · FY2009 · CA · contact PI
X-RAR alpha proteins: Molecualr Pathogenesis of Acute Promyelocytic Leukemia$348,711
R37 · FY2009 · CA · contact PI
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE$332,386
P50 · FY2009 · CA · contact PI
ANIMAL MODELS CORE$296,429
P50 · FY2009 · CA · contact PI
Control of Protein Translation in Cancer Pathogenesis$697,531
U01 · FY2008 · CA · contact PI
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE$380,335
P50 · FY2008 · CA · contact PI
Fusion Proteins in the Molecular Pathogenesis of APL$351,467
R01 · FY2008 · CA · contact PI
X-RAR alpha proteins: Molecualr Pathogenesis of Acute Promyelocytic Leukemia$348,711
R37 · FY2008 · CA · contact PI
PTEN and ontogenesis and tumor suppression$344,028
R01 · FY2008 · CA · contact PI
ANIMAL MODELS CORE$338,708
P50 · FY2008 · CA · contact PI
Role of POZ-zinc finger proteins in hemopoietic malignacies$330,443
R01 · FY2008 · CA · contact PI
Control of Protein Translation in Cancer Pathogenesis$644,970
U01 · FY2007 · CA · contact PI
X-RAR alpha proteins: Molecualr Pathogenesis of Acute Promyelocytic Leukemia$374,556
R37 · FY2007 · CA · contact PI
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE$372,066
P50 · FY2007 · CA · contact PI
Role of POZ-zinc finger proteins in hemopoietic malignacies$354,934
R01 · FY2007 · CA · contact PI
ANIMAL MODELS CORE$330,882
P50 · FY2007 · CA · contact PI
PTEN and Ontogenesis and Tumor Suppression$270,145
R01 · FY2007 · CA · contact PI
Fusion Proteins in the Molecular Pathogenesis of APL$238,280
R01 · FY2007 · CA · contact PI
Fusion Proteins in the Molecular Pathogenesis of APL$151,281
R01 · FY2007 · CA · contact PI
PTEN and Ontogenesis and Tumor Suppression$96,043
R01 · FY2007 · CA · contact PI
Control of Protein Translation in Cancer Pathogenesis$551,829
U01 · FY2006 · CA · contact PI
Fusion Proteins in the Molecular Pathogenesis of APL$403,832
R01 · FY2006 · CA · contact PI
PLM, PLZF, NPM and NuMA in the Molecular Pathogenesis of APL$371,378
R37 · FY2006 · CA · contact PI
PTEN and Ontogenesis and Tumor Suppression$348,003
R01 · FY2006 · CA · contact PI
Role of POZ-zinc in hemopoietic malignacies$337,308
R01 · FY2006 · CA · contact PI
MOLECULAR CARCINOGENESIS IN THE MOUSE AND HUMAN PROSTATE$165,107
P50 · FY2006 · CA · contact PI
ANIMAL MODELS CORE$146,746
P50 · FY2006 · CA · contact PI
Control of Protein Translation in Cancer Pathogenesis$551,327
U01 · FY2005 · CA
Fusion Proteins in the Molecular Pathogenesis of APL$392,550
R01 · FY2005 · CA
PTEN and Ontogenesis and Tumor Suppression$356,378
R01 · FY2005 · CA
PML, PLZF, NPM AND NUMA IN THE PATHOGENESIS OF APL$351,731
R01 · FY2005 · CA
Role of POZ-zinc in hemopoietic malignacies$345,425
R01 · FY2005 · CA
2005 Cancer Models and Mechanisms Gordon Conference$10,000
R13 · FY2005 · CA
Control of Protein Translation in Cancer Pathogenesis$543,556
U01 · FY2004 · CA
FUSION PROTEINS IN THE MOLECULAR PATHOGENESIS OF APL$374,625
R01 · FY2004 · CA
PTEN and Ontogenesis and Tumor Suppression$356,378
R01 · FY2004 · CA
PML, PLZF, NPM AND NUMA IN THE PATHOGENESIS OF APL$351,731
R01 · FY2004 · CA
Role of POZ-zinc in hemopoietic malignacies$345,425
R01 · FY2004 · CA
THE APL PARADIGM FOR ABERRANT TRANSCRIPTION, CANCER AND$537,580
U01 · FY2003 · CA
FUSION PROTEINS IN THE MOLECULAR PATHOGENESIS OF APL$374,625
R01 · FY2003 · CA
PTEN and Ontogenesis and Tumor Suppression$355,109
R01 · FY2003 · CA
PML, PLZF, NPM AND NUMA IN THE PATHOGENESIS OF APL$351,731
R01 · FY2003 · CA
CANCER GENETICS TRAINING PROGRAM$108,940
T32 · FY2003 · CA
THE APL PARADIGM FOR ABERRANT TRANSCRIPTION, CANCER AND$521,922
U01 · FY2002 · CA
FUSION PROTEINS IN THE MOLECULAR PATHOGENESIS OF APL$374,625
R01 · FY2002 · CA
PML, PLZF, NPM AND NUMA IN THE PATHOGENESIS OF APL$351,731
R01 · FY2002 · CA
PTEN AND ONTOGENESIS AND TUMOR SUPPRESSION$286,367
R01 · FY2002 · CA
CANCER GENETICS TRAINING PROGRAM$76,601
T32 · FY2002 · CA
PROSTATE CANCER IMMUNOLOGY AND VACCINE DEVELOPMENT$0
P50 · FY2002 · CA
MOLECULAR ANALYSIS OF CARCINOGENESIS IN THE PROSTATE$0
P50 · FY2002 · CA
PROSTATE CANCER IMMUNOLOGY AND VACCINE DEVELOPMENT$0
P50 · FY2002 · CA
MOLECULAR ANALYSIS OF CARCINOGENESIS IN THE PROSTATE$0
P50 · FY2002 · CA
THE APL PARADIGM FOR ABERRANT TRANSCRIPTION, CANCER AND$506,721
U01 · FY2001 · CA
FUSION PROTEINS IN THE MOLECULAR PATHOGENESIS OF APL$374,625
R01 · FY2001 · CA
PML, PLZF, NPM AND NUMA IN THE PATHOGENESIS OF APL$351,731
R01 · FY2001 · CA
GAT62 IN ONTOGENESIS, HEMATOPOIESIS, AND LEUKEMOGENESIS$296,752
P01 · FY2001 · CA
PTEN AND ONTOGENESIS AND TUMOR SUPPRESSION$256,242
R01 · FY2001 · CA
CANCER GENETICS TRAINING PROGRAM$98,856
T32 · FY2001 · CA
POK PROTEINS IN ONTOGENESIS, LYMPHOPOIESIS, AND LYMPHOMAGENESIS$76,744
P01 · FY2001 · CA
PROSTATE CANCER IMMUNOLOGY AND VACCINE DEVELOPMENT$0
P50 · FY2001 · CA
MOLECULAR ANALYSIS OF CARCINOGENESIS IN THE PROSTATE$0
P50 · FY2001 · CA
THE APL PARADIGM FOR ABERRANT TRANSCRIPTION, CANCER AND$491,961
U01 · FY2000 · CA
FUSION PROTEINS IN THE MOLECULAR PATHOGENESIS OF APL$374,625
R01 · FY2000 · CA
PTEN AND ONTOGENESIS AND TUMOR SUPPRESSION$248,780
R01 · FY2000 · CA
GAT62 IN ONTOGENESIS, HEMATOPOIESIS, AND LEUKEMOGENESIS$244,344
P01 · FY2000 · CA
POK PROTEINS IN ONTOGENESIS, LYMPHOPOIESIS, AND LYMPHOMAGENESIS$183,052
P01 · FY2000 · CA
CANCER GENETICS TRAINING PROGRAM$165,672
T32 · FY2000 · CA